Computational Development of Novel Dyslipidemia Therapeutic Candidates to Disrupt ApoC-III Conformation

项目摘要 心血管疾病（CVD）是美国和发展中国家的重大威胁 遍布地球仪。与低密度脂蛋白胆固醇（LDL-c）升高广泛相关， 治疗干预主要集中在降低LDL-C血浆水平。尽管 尽管有能力在治疗上达到这些目标水平，但许多患者仍维持高心血管风险 数据区.这种治疗悖论的一个因果贡献者是富含甘草酸的药物的发展。 脂蛋白（TRL）颗粒，高度致动脉粥样硬化的残余颗粒，是受损的 脂肪酶催化剂对目前FDA批准的降LDL-c药物表现出耐药性， 尽管LDL-C过度降低，这些颗粒仍保持显著的心血管风险。它有 已经确定高载脂蛋白C-III（ApoC-III）是TRL颗粒的标志。的 ApoC-III的险恶性质是众所周知的，因为它具有关键功能，包括但不限于 不限于：抑制脂蛋白脂酶（LPL），损害HDL胆固醇流出， 脂蛋白颗粒肝摄取延迟。作为一种潜在的解决方案，iMBP正在开发新的 靶向ApoC-III的治疗性化合物。我们目前的研究工作在计算上 鉴定了在结合后诱导ApoC-III靶标构象畸变的潜力。 由于分子中的高度柔性铰链区是ApoC-III稳定在 脂蛋白颗粒，诱导构象变化可以提供一种独特的治疗方法， 降低TRL水平的作用方式。这项概念验证工作是在计算上 重新设计目前的专利治疗候选药物，以增强ApoC-III失真 能力的然后将表达表达文库，并且将功能性地表达最佳候选者。 测试结合力。分为2个具体目标，可行性测试的最终评估将决定 由于结合而达到的变形程度。这场决赛的里程碑 目的是鉴定一种结合ApoC-III并在其分子中产生可测量的变化的分子。 随着蛋白质端到端距离的增加，呈现出构象。满意 这一里程碑将导致SBIR第二阶段计划，该计划将进一步评估 人工诱导的ApoC-III构象畸变可能会使其脂蛋白不稳定， 颗粒结合特性，并有助于血浆清除，最终导致临床前 试验.

Project Abstract Cardiovascular Disease (CVD) is a significant threat in the United States and developing countries across the globe. Widely associated with elevated low density lipoprotein cholesterol (LDL-c), therapeutic interventions are primarily focused on reduction of LDL-c plasma levels. Despite the ability to therapeutically reach these target levels, many patients maintain high cardiovascular risk profiles. A causal contributor to this therapeutic paradox is the development of triglyceride-rich lipoprotein (TRL) particles, highly atherogenic remnant particles that are the result of impaired lipase catabolism. Exhibiting resistance to current FDA approved LDL-c lowering medications, these particles maintain significant cardiovascular risk despite the over lowering of LDL-c. It has been determined that high apolipoprotein C-III (ApoC-III) is a hallmark of TRL particles. The sinister nature of ApoC-III is well established as it possesses key functions that include, but are not limited to; inhibition of Lipoprotein Lipase (LPL), impairment of HDL cholesterol efflux and retardation of lipoprotein particle hepatic uptake. As a potential solution, iMBP is developing new therapeutic compounds that target ApoC-III. Our current research efforts have computationally identified the potential to induce a conformational distortion in the ApoC-III target upon binding. Due to a highly flexible hinge region in the molecule that is necessary for ApoC-III to stabilize on lipoprotein particles, the induction of a conformational change could provide a unique therapeutic mode of action in action for reducing TRL levels. This proof-of-concept work is to computationally reengineer a current proprietary therapeutic candidate to augmented ApoC-III distortion capabilities. An expression library will then be expressed and top candidates will be functionally tested for binding. Split into 2 Specific Aims, the final evaluation of feasibility testing will determine the degree of distortion that is achieved as a consequence of binding. The milestone for this final Aim is the identification of a molecule that binds ApoC-III and creates a measurable change in its conformation exhibited as an increase in the protein’s end to end distance. The satisfaction of this milestone would lead to a SBIR Phase 2 plan that would further evaluate the influence that an artificially induced ApoC-III conformational distortion could play in destabilizing its lipoprotein particle binding characteristics and assist in plasma clearance that would culminate in pre-clinical testing.